author-photo

Monica Hellesøy

Haukeland University Hospital

12

Papers

8

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Implementing a functional precision medicine tumor board for acute myeloid leukemia.

2021 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (0)
Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis

2021 Molecular Oncology
Show All
- Source
- Cite
- Save
Citations (1)
The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Single Cell Detection of the p53 Protein by Mass Cytometry

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (0)
A 36-Dimensional Cytometry by Time of Flight (CyTOF) Analysis of De Novo Acute Myeloid Leukemia (AML) Patients Eligible for Intensive Chemotherapy

2018 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Single Cell-Level Signaling Profiling of Acute Myeloid Leukemia Following Treatment with Axl Kinase Inhibitor BGB324

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)